H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Stemline Therapeutics Inc (NASDAQ: STML) today and set a price target of $38. The company’s shares closed yesterday at $19.60, close to its 52-week high of $20.55.
Selvaraju noted:
“We note that this is substantially better than the 21% OS-12 generated by Avastin alone in responders, according to an article published in 1141-1146, 2017. SL-701 was well-tolerated and had a manageable side effect profile. We believe Stemline could leverage potential immune-related biomarker parameters in a future registration- directed trial of SL-701 to screen GBM patients who are most likely to become long-term survivors. Furthermore, we remind investors that SL-701 has historically been underrated and de-emphasized by the market because of the grim nature of GBM; nevertheless, this clinical data presented at ASCO appears to indicate that there is some reason to believe in SL-701’s future, despite the challenge posed by the indication.”
According to TipRanks.com, Selvaraju is a 2-star analyst with an average return of 0.8% and a 41.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Stemline Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $38.
See today’s analyst top recommended stocks >>
The company has a one-year high of $20.55 and a one-year low of $7.30. Currently, Stemline Therapeutics Inc has an average volume of 301.5K.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. It develops a discovery platform called StemScreen, which identifies novel compounds that target and kill cancer stem cells.
